Kazia Therapeutics announced a $40 million public offering of American Depositary Shares and warrants, with potential additional proceeds of $80 million if warrants are exercised. The funds will primarily support clinical development of their cancer drug paxalisib, targeting breast cancer and other cancers. The offering is expected to close by August 31, 2026, and is managed by several investment banks. This capital raise aims to advance ongoing and planned clinical trials for paxalisib, which has shown promise in multiple cancer types and holds several FDA designations.
BRC Group Holdings announced it will fully redeem $142.1 million of its 6.50% Senior Notes due 2026 on September 29, 2026. The redemption price will be 100% of the principal plus accrued interest up to but excluding the redemption date. Following red...
Ethereum price hovered around $2,500 after a 35% rise since mid-August, facing resistance near $2,550 amid an overbought daily RSI of 77.4. The price formed an ascending triangle pattern, suggesting potential for a breakout above $2,533, which could ...
HEICO reported another strong quarterly earnings beat with excellent organic growth, continuing its trend of solid financial performance. Despite the positive results, the stock showed little movement, reflecting investor caution about the sustainabi...
Retirees seeking sustainable income face challenges as core dividend ETFs like SCHD yield around 3%, while high-yield ETFs carry credit risk and limited growth. A balanced approach using core holdings such as SCHD combined with selective satellite ET...
Mid-America Apartment Communities (MAA) announced it will redeem all outstanding 8.50% Series I Cumulative Redeemable Preferred Shares on October 1, 2026, at $50 per share plus accrued dividends. This move will stop dividend accrual on these shares a...
